Reactive Oxygen Species (ROS) News and Research

RSS

Researchers uncover why ointment and photodynamic therapy cause pain in skin cancer patients

Apply the ointment, light on, light off - that's how easy it is to cure various forms of non-melanoma skin cancer. However, the majority of patients suffer severe pain during the so-termed photodynamic therapy.

23 Jun 2012

Emory scientists identify new type of anti-inflammatory compound

Scientists at Emory University School of Medicine have identified a new type of anti-inflammatory compound that may be useful in treating a wide range of conditions, including neurodegenerative and autoimmune diseases. These compounds inhibit the enzyme Nox2, part of a family of enzymes responsible for producing reactive oxygen species (ROS).

22 Jun 2012

Psoriasis TNF-α therapeutic effects mediated by MSC antioxidant reduction

The therapeutic effects of tumor necrosis factor-α inhibitors in psoriasis occur through a reduction in the antioxidant response of mesenchymal stem cells, suggest study findings.

15 Jun 2012

AMPK enzyme promotes survival of cancer cells: Research

A molecule thought to limit cell proliferation also helps cancer cells survive during initial tumor formation and when the wayward cells spread to other organs in the body, researchers at the University of Illinois at Chicago College of Medicine have found.

15 Jun 2012

The truth about chocolate: does it really contain flavonoids?

There have been many news stories over the years about chocolate and whether it is good or bad for you. The stories often comment on a chemical constituent of chocolate: flavonoids. But what are flavonoids? Does chocolate even contain them? And why should we care if it does?

18 May 2012

Spectrum initiates ZEVALIN and MGd Phase 2 combination study in NHL

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the initiation of a Phase 2 study evaluating ZEVALIN (ibritumomab tiuxetan) Injection for intravenous use + rituximab in combination with motexafin gadolinium (MGd) in patients with rituximab-refractory low-grade or follicular B-cell non-Hodgkin's lymphoma.

18 May 2012

Reducing iron levels in blood plasma may protect brain from changes related to AD

Alzheimer's disease (AD) is now the sixth leading cause of death among Americans, affecting nearly 1 in 8 people over the age of 65. There is currently no treatment that alters the course of this disease. However, an increasing amount of evidence suggests that changes in the way the body handles iron and other metals like copper and zinc may start years before the onset of AD symptoms. A new study shows that reducing iron levels in blood plasma may protect the brain from changes related to AD.

11 Apr 2012

Researchers identify mechanism of TRPM2 regulation

Professor Makoto TOMINAGA from National Institute for Physiological Sciences (Okazaki Institute for Integrative Bioscience), National Institutes of Natural Sciences, and his research team member Ms. Makiko KASHIO have identified the mechanism through which TRPM2 is activated by body temperature with hydrogen peroxide (a kind of reactive oxygen species) produced by immune reactions.

10 Apr 2012

New hypothesis may be a game changer in the evolution arena

A new hypothesis posed by a University of Tennessee, Knoxville, associate professor and colleagues could be a game changer in the evolution arena. The hypothesis suggests some species are surviving by discarding genes and depending on other species to play their hand.

5 Apr 2012

New treatment approach halts spread of cancer cells into normal brain tissue

Treating invasive brain tumors with a combination of chemotherapy and radiation has improved clinical outcomes, but few patients survive longer than two years after diagnosis. The effectiveness of the treatment is limited by the tumor's aggressive invasion of healthy brain tissue, which restricts chemotherapy access to the cancer cells and complicates surgical removal of the tumor.

29 Mar 2012

Researchers design new treatment approach for invasive brain tumors

Researchers from Emory and the Georgia Institute of Technology have designed a new treatment approach that appears to halt the spread of cancer cells into normal brain tissue in animal models.

29 Mar 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Switch may release fuel and materials for rapid growth and formation of layers that later become organs

Shortly after a mouse embryo starts to form, some of its stem cells undergo a dramatic metabolic shift to enter the next stage of development, Seattle researchers report today. These stem cells start using and producing energy like cancer cells.

26 Mar 2012

Study identifies ROS in the gaseous phase of cigarette smoke

A team of researchers led by A. K. Rajasekaran, PhD, Director of the Nemours Center for Childhood Cancer Research, has shown that a key protein involved in cell function and regulation is stopped by a substance present in cigarette smoke.

22 Mar 2012

Desflurane may be safer anesthetic option for patients with AD

In a study that will appear in Annals of Neurology and has received early online release, Massachusetts General Hospital (MGH) researchers report that administration of isoflurane impaired the performance of mice on a standard test of learning and memory - a result not seen when another anesthetic, desflurane, was administered.

2 Mar 2012

Combination treatment for pancreatic cancer increases intratumoral gemcitabine levels

Oncologists who treat patients with pancreatic cancer may be one step closer to understanding why gemcitabine, the only currently available treatment, works in some cases but not in others, according to a paper in Cancer Discovery, a journal of the American Association for Cancer Research.

29 Feb 2012

Telomerase reactivation in malignant cells after genomic instability causes cancer progression

Inhibiting telomerase, an enzyme that rescues malignant cells from destruction by extending the protective caps on the ends of chromosomes, kills tumor cells but also triggers resistance pathways that allow cancer to survive and spread, scientists report in the Feb. 17 issue of Cell.

21 Feb 2012

Multiple DNA repair defect in monocytes

Scientists working with Professor Bernd Kaina of the Institute of Toxicology at the Medical Center of Johannes Gutenberg University Mainz have demonstrated for the first time that certain cells circulating in human blood - so-called monocytes - are extremely sensitive to reactive oxygen species (ROS).

3 Feb 2012

Researchers identify mechanism that leads to ischemia-reperfusion damage

For patients with incurable pulmonary conditions, a lung transplantation is the only available treatment option. However, suitable donor organs are scarce, and even getting them to prospective recipients is not easy. As Professor Alexander Dietrich of the Walther Straub Institute of Pharmacology and Toxicology at LMU explains, "An isolated lung which is no longer perfused with blood can become so severely damaged that it is no longer functional. This so-called ischemia-reperfusion injury is one of the major problems in the field of lung transplantation."

2 Feb 2012